Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cisplatin/epinephrine injectable gel.

H Malhotra1, G L Plosker

  • 1Adis International Limited, Auckland, New Zealand.

Drugs & Aging
|December 12, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quality-of-care indicators for oncology management: an analysis of Asia-Pacific healthcare and oncology indicators.

ESMO open·2025
Same author

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer.

ESMO open·2022
Same author

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma.

ESMO open·2021
Same author

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

SU-E-T-452: Impact of Abdominal Compression on the Tumor Motion in the Treatment of NSCLC Using Stereotactic Body Radiosurgery.

Medical physics·2017
Same author

SU-E-J-25: Dosimetric Characterization of an OBI System Using Gafchromic XRQA2 Film.

Medical physics·2017
Same journal

Leveraging Real-World Data for Clinical Decision Making in Geriatric Oncology.

Drugs & aging·2026
Same journal

Drug Utilisation of Fall-Risk-Increasing Drugs (FRIDs) and Risk of Hospitalisation: A Nested Case-Control Study Among Community-Dwelling Older Adults.

Drugs & aging·2026
Same journal

Gabapentinoid Use and Risk of Alzheimer's Disease-Related Dementias: A Systematic Review and Meta-analysis of Observational Studies.

Drugs & aging·2026
Same journal

Development and Validation of Prescribing Appropriateness Criteria (PAC) for Sri Lankan Older Adults.

Drugs & aging·2026
Same journal

Adapting the Geriatric Medicine 5Ms Framework to Geriatric Dermatology.

Drugs & aging·2026
Same journal

External Validation of a Community Pharmacy-Based Screening Tool for Frailty That Uses Routinely Collected Data.

Drugs & aging·2026
See all related articles

Cisplatin/epinephrine injectable gel offers palliative treatment for accessible solid tumors. This formulation enhances local cisplatin concentration, minimizing systemic exposure and associated toxicities.

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Delivery Systems

Background:

  • Cisplatin is a widely used chemotherapy agent, but its systemic administration is limited by significant toxicities.
  • Developing localized drug delivery systems can improve therapeutic efficacy and reduce side effects.
  • Intratumoral injection offers a targeted approach to deliver chemotherapy directly to the tumor site.

Purpose of the Study:

  • To evaluate the efficacy and safety of cisplatin/epinephrine injectable gel for the palliative treatment of accessible, inoperable, metastatic, or recurrent solid tumors.
  • To assess the pharmacokinetic profile of cisplatin when delivered via the injectable gel formulation.
  • To compare the efficacy of cisplatin/epinephrine injectable gel against placebo in head and neck squamous cell carcinoma.

Main Methods:

Related Experiment Videos

  • Double-blind, randomized trials were conducted to compare cisplatin/epinephrine injectable gel with placebo.
  • Non-comparative clinical trials assessed the gel's impact on tumor size and local symptoms in various cancers.
  • Pharmacokinetic studies measured cisplatin and epinephrine concentrations in plasma and tissues after intratumoral injection.

Main Results:

  • Cisplatin/epinephrine injectable gel demonstrated superior efficacy compared to placebo in palliative treatment of recurrent and resistant head and neck squamous cell carcinoma.
  • Significant reductions in tumor size and improvements in local symptoms were observed in patients with metastatic breast cancer, malignant melanoma, esophageal carcinoma, and hepatic tumors.
  • The vasoconstrictor epinephrine effectively limited cisplatin diffusion into systemic circulation, resulting in high intratumoral concentrations and low plasma levels.

Conclusions:

  • Cisplatin/epinephrine injectable gel is an effective option for palliative treatment of accessible metastatic or recurrent solid tumors.
  • The formulation achieves targeted delivery of cisplatin, enhancing local efficacy while minimizing systemic toxicity.
  • Adverse events are primarily localized to the injection site, with no reported systemic toxicities like nephrotoxicity, neurotoxicity, or ototoxicity.